Eleva Capital’s Mineralys Therapeutics MLYS Stock Holding History

Eleva Capital’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$463K	Hold	17,081	–	–	0.13%	17
2026 Q1	$463K	Buy	+17,081	New	+$501K	0.13%	17

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Eleva Capital's MLYS Position: Q2 2026 in Review

Eleva Capital held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 17,081 shares worth $463K. The position accounts for 0.13% of the portfolio, ranked #17.

Eleva Capital first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Eleva Capital held 17,081 shares of Mineralys Therapeutics worth $463K as of Q2 2026.
Eleva Capital left its Mineralys Therapeutics share count unchanged in Q2 2026.
Mineralys Therapeutics made up 0.13% of Eleva Capital's portfolio in Q2 2026, its #17 holding.
Eleva Capital first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Eleva Capital's 13F filing for Q2 2026, filed 2 Jul 2026.